Skip to content

Effect of lorazepam on the disorder of catatonia

Catatonia and Lorazepam - A Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/035255
Enrollment
30
Registered
2021-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F315- Bipolar disorder, current episodedepressed, severe, with psychotic features Health Condition 2: F312- Bipolar disorder, current episodemanic severe with psychotic features Health Condition 3: F23- Brief psychotic disorder Health Condition 4: F202- Catatonic schizophrenia

Interventions

None listed

Sponsors

HBT Medical College and Dr RN Cooper Municipal General Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with Catatonia as per DSM-5 2. Patients whose records were available for at least 3 follow-ups 3. Patients treated with Lorazepam

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with organic cause of catatonia 2. Patients who had history of being prescribed Benzodiazepines 2 weeks before presenting to OPD 3. Patients with history of substance use

Design outcomes

Primary

MeasureTime frame
Observation of Effect of MedicationsTimepoint: Respective follow-ups of the patient at first visit Day 0, Day 7 and day 14 and day 21

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactAstik Mane

Dr. RNCH and HBT medical college

kitsaenam@gmail.com07977396991

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026